Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Pharmaceutics

• Publication date

  2013-04-24

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/mp300582sPMID 23560393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

  2013cited by this paper
• Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

  2013cited by this paper
• The role of inter-segmental differences in P-glycoprotein expression and activity along the rat small intestine in causing the double-peak phenomenon of substrate plasma concentration.

  2013cited by this paper
• Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers

  2012cited by this paper
• Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

  2012cited by this paper
• Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist

  2012cited by this paper
• Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

  2012cited by this paper
• An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder

  2011cited by this paper
• Species Difference in the Effect of Grapefruit Juice on Intestinal Absorption of Talinolol between Human and Rat

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.

  2009cited by this paper
• Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol.

  2009cited by this paper
• Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans

  2008cited by this paper
• Involvement of organic anion transport system in transdermal absorption of flurbiprofen.

  2007cited by this paper
• Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3

  2007cited by this paper
• Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder Function

  2007cited by this paper
• Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans

  2007cited by this paper
• Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.

  2007cited by this paper
• PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS

  2006cited by this paper
• What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.

  2006cited by this paper
• Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies.

  2005cited by this paper
• The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen

  2005cited by this paper
• EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS

  2005cited by this paper
• Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.

  2005cited by this paper
• The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS

  2005cited by this paper
• Peptide transporters: structure, function, regulation and application for drug delivery.

  2004cited by this paper
• In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System

  2004cited by this paper
• A Modified Two-Portion Absorption Model to Describe Double-Peak Absorption Profiles of Ranitidine

  2003cited by this paper
• Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane

  2003cited by this paper
• Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena.

  2003cited by this paper
• pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions

  2003cited by this paper
• Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein

  2001cited by this paper
• Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1.

  2001cited by this paper
• A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.

  2001cited by this paper
• Bioavailability and Pharmacokinetics of Lorazepam after Intranasal, Intravenous, and Intramuscular Administration

  2001cited by this paper
• Cimetidine absorption and elimination in rat small intestine.

  2000cited by this paper
• Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption.

  2000cited by this paper
• Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells.

  2000cited by this paper
• Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.

  1999cited by this paper
• Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs.

  1999cited by this paper
• In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth

  1997cited by this paper
• Analysis of Drug Permeation Across Caco-2 Monolayer: Implication for Predicting In Vivo Drug Absorption

  1997cited by this paper
• Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo

  1996cited by this paper
• Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs

  1995cited by this paper
• A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

  1995cited by this paper
• Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration–Time Profile

  1993cited by this paper
• Transport of celiprolol across human intestinal epithelial (Caco‐2) cells: mediation of secretion by multiple transporters including P‐glycoprotein

  1993cited by this paper
• Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

  1991cited by this paper
• Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

  1990cited by this paper
• Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability.

  1989cited by this paper
• Measurement of gastrointestinal pH profiles in normal ambulant human subjects.

  1988cited by this paper
• The absorption of β‐adrenoceptor antagonists in rat in‐situ small intestine; the effect of lipophilicity

  1985cited by this paper
• On the mechanism of intestinal absorption of drugs.

  1959cited by this paper

• Effect of deep eutectic solvents on the enantiomeric separation of mirabegron by cyclodextrin-electrokinetic chromatography. Application to the analysis of pharmaceutical and biological matrices

  2026cites this paper
• Chemoenzymatic synthesis of mirabegron using an engineered styrene monooxygenase

  2026cites this paper
• In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter

  2024cites this paper
• Physiologically based in vitro - In vivo correlation of modified release oral formulations with non-linear intestinal absorption: A case study using mirabegron.

  2024cites this paper
• Genetic Variation in CYP2D6, UGT1A4, SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron

  2024cites this paper
• Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron

  2024influential citation
• Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

  2023cites this paper
• Urinary Incontinence in People Living with Cognitive Impairment

  2021cites this paper
• A simple decision tree suited for identification of early oral drug candidates with likely pharmacokinetic nonlinearity by intestinal CYP3A saturation.

  2020cites this paper
• Drug interactions in urology - what to watch out for

  2020cites this paper
• Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment

  2019cites this paper
• Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase

  2018influential citation
• Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient

  2018cites this paper
• Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.

  2017cites this paper
• Characterization of the membrane transporter OATP1A2 activity towards different classes of drugs

  2017cites this paper
• Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder.

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• CELL MODELS FOR STUDYING THE INTERPLAY BETWEEN CONJUGATIVE METABOLISM AND EFFLUX TRANSPORTERS: ESTABLISHING UGT1A1, UGT2B7 AND MRP3 TRANSFECTED MDCK CELL LINES

  2016cites this paper
• Predicting liver metastasis of gastrointestinal tract cancer by diffusion-weighted imaging of apparent diffusion coefficient values.

  2016cites this paper
• Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.

  2015influential citation
• Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy Subjects

  2014cites this paper
• Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.

  2014cites this paper
• Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies

  2013cites this paper
• Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist

  2013cites this paper